数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
周峰 Chief Executive Officer and Director 29 5.00万美元 212.50 2021-08-13
郑军 Director 44 未披露 未持股 2021-08-13
李俊松 Independent Director 57 未披露 未持股 2021-08-13
范文伟 Independent Director 51 未披露 未持股 2021-08-13
Xiaodong Ji Independent Director 51 未披露 未持股 2021-08-13

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
周峰 Chief Executive Officer and Director 29 5.00万美元 212.50 2021-08-13
Wang L. Lee Chief Financial Officer 43 0.81万美元 未持股 2021-08-13
邓京振 Chief Scientific Officer and Chief Operation Officer 61 5.00万美元 未持股 2021-08-13

董事简历

中英对照 |  中文 |  英文
周峰

周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。


Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。
Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
郑军

郑军于2018年12月31日被任命为公司董事。郑先生从1999年至2004年曾任江西博世达制药有限公司销售区域经理,以及台州九天药业有限公司部门经理和副总经理。郑先生于2005年至2012年间担任总经理。郑先生于2013年至2015年间担任台州仁济中药饮片有限公司总经理,并于2016年起担任江苏健康药业投资管理有限公司总经理。 到2017年。郑先生现为台州素悬堂副总裁。 郑先生于1999年在江南大学无锡轻工业大学获得学士学位。


Jun Zheng has been appointed as our director upon closing of our IPO on December 31 2018. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004 and a department manager and deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Taizhou Suxuantang. Mr. Zheng received his bachelor’s degree from Jiangnan University Wuxi Light Industry University in 1999.
郑军于2018年12月31日被任命为公司董事。郑先生从1999年至2004年曾任江西博世达制药有限公司销售区域经理,以及台州九天药业有限公司部门经理和副总经理。郑先生于2005年至2012年间担任总经理。郑先生于2013年至2015年间担任台州仁济中药饮片有限公司总经理,并于2016年起担任江苏健康药业投资管理有限公司总经理。 到2017年。郑先生现为台州素悬堂副总裁。 郑先生于1999年在江南大学无锡轻工业大学获得学士学位。
Jun Zheng has been appointed as our director upon closing of our IPO on December 31 2018. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004 and a department manager and deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Taizhou Suxuantang. Mr. Zheng received his bachelor’s degree from Jiangnan University Wuxi Light Industry University in 1999.
李俊松

李俊松在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。李先生在中医药行业有着20多年的丰富经验。自2009年,李先生担任南京中医药大学研究员,并于1986年至2003年,担任南京中医药大学副教授。李先生于1986年毕业于南京中医药大学,并获得中医药文学学士学位,2002年获得中医药硕士学位,2006年获得上海中医药大学博士学位。


Junsong Li has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Li has over 20 year-experience in the TCM industry. Mr. Li has served as the researcher of Nanjing TCM University since 2009. From 1986 to 2003 Mr. Li worked as an associate professor of Nanjing TCM Hospital. Mr. Li graduated from Nanjing TCM University with a Bachelor of Arts in TCM in 1986 and a Master’s Degree in TCM in 2002. Mr. Li obtained his PhD from Shanghai TCM University in 2006.
李俊松在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。李先生在中医药行业有着20多年的丰富经验。自2009年,李先生担任南京中医药大学研究员,并于1986年至2003年,担任南京中医药大学副教授。李先生于1986年毕业于南京中医药大学,并获得中医药文学学士学位,2002年获得中医药硕士学位,2006年获得上海中医药大学博士学位。
Junsong Li has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Li has over 20 year-experience in the TCM industry. Mr. Li has served as the researcher of Nanjing TCM University since 2009. From 1986 to 2003 Mr. Li worked as an associate professor of Nanjing TCM Hospital. Mr. Li graduated from Nanjing TCM University with a Bachelor of Arts in TCM in 1986 and a Master’s Degree in TCM in 2002. Mr. Li obtained his PhD from Shanghai TCM University in 2006.
范文伟

范文伟在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。范先生现任中国注册会计师事务所—北京华申会计师事务所合伙人,负责国际审计监督,包括对几家跨国公司中国子公司的财务报表进行审计。他的职业生涯始于2000年由普华永道收购的世永中和会计师事务所。范先生拥有注册会计师和注册税务师证书。范先生于1992年毕业于江苏财经大学,并获得学士学位。


Wenwei Fan has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Fan currently is a Partner of a Chinese Certified Public Accountant firm, Beijing Huashen Accounting Firm, where he is in charge of supervising international auditing, including auditing financial statements for Chinese subsidiaries of several multinational companies. He started his career with ShiyongZhonghe Accounting firm, which was acquired by PricewaterhouseCoopers in 2000. Mr. Fan is a Certified Public Accountant and Certified Tax Agent in China. He graduated from Jiangsu University of Finance and Economics in 1992 with a bachelor’s degree.
范文伟在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。范先生现任中国注册会计师事务所—北京华申会计师事务所合伙人,负责国际审计监督,包括对几家跨国公司中国子公司的财务报表进行审计。他的职业生涯始于2000年由普华永道收购的世永中和会计师事务所。范先生拥有注册会计师和注册税务师证书。范先生于1992年毕业于江苏财经大学,并获得学士学位。
Wenwei Fan has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Fan currently is a Partner of a Chinese Certified Public Accountant firm, Beijing Huashen Accounting Firm, where he is in charge of supervising international auditing, including auditing financial statements for Chinese subsidiaries of several multinational companies. He started his career with ShiyongZhonghe Accounting firm, which was acquired by PricewaterhouseCoopers in 2000. Mr. Fan is a Certified Public Accountant and Certified Tax Agent in China. He graduated from Jiangsu University of Finance and Economics in 1992 with a bachelor’s degree.
Xiaodong Ji

Xiaodong Ji于2019年10月成立Jiangsu Sutaitang E-Commerce Co., Ltd.,现任SutaitangCEO。他还是江苏健康药业投资有限公司的副总经理。他在企业管理,品牌链运营和市场营销方面拥有二十年的丰富经验。加入中国苏轩堂药业有限公司之前,他分别担任过东方紫酒,正德药业,中国一带购物商城有限公司(中宗投集团的子公司,“购物商城”)的首席执行官。他负责东方紫酒和正德药业的企业管理和渠道建设。东方紫酒创造了中国第五大葡萄酒类别-紫葡萄酒。正德药业是由吉林紫鑫药业股份有限公司控制的品牌渠道企业,吉林紫鑫药业股份有限公司在深圳证券交易所上市。他负责购物中心的战略规划和生态链建设,这是“一带一路”倡议下的世界购物中心体系。他拥有北京中医药大学的学士学位。


Xiaodong Ji was appointed as our director on May 22 2021. Mr. Ji established Jiangsu Sutaitang E-Commerce Co., Ltd. “Sutaitang” in October 2019 and currently serves as the CEO of Sutaitang. He is also the deputy general manager of Jiangsu Health Pharmaceutical investment Co., Ltd. Mr. Ji has rich experience of two decades in corporation management, brand chain operation and marketing. Prior to joining us, Mr. Ji has served as CEOs of Dongfang Purple Wine, Zhengde Pharmaceutical, China Belt and Road Shopping Mall Co., Ltd. (the subsidiary of Zhong Zong Tou Group, “Shopping Mall”), respectively. Mr. Ji was responsible for the enterprise management and channel construction of Dongfang Purple Wine and Zhengde Pharmaceutical. Dongfang Purple Wine creates the fifth largest category of wine in China - Purple wine (purple wine is a fine wine made from mulberry fruit). Zhengde pharmaceutical is a brand channel enterprise controlled by Jilin Zixin Pharmaceutical Industrial Co., Ltd. which is listed on Shenzhen Stock Exchange. Mr. Ji was in charge of the strategic planning and ecological chain construction of Shopping Mall, which is a world shopping mall system under the Belt and Road Initiative. Mr. Ji earned his bachelor degree from Beijing University of Chinese Medicine.
Xiaodong Ji于2019年10月成立Jiangsu Sutaitang E-Commerce Co., Ltd.,现任SutaitangCEO。他还是江苏健康药业投资有限公司的副总经理。他在企业管理,品牌链运营和市场营销方面拥有二十年的丰富经验。加入中国苏轩堂药业有限公司之前,他分别担任过东方紫酒,正德药业,中国一带购物商城有限公司(中宗投集团的子公司,“购物商城”)的首席执行官。他负责东方紫酒和正德药业的企业管理和渠道建设。东方紫酒创造了中国第五大葡萄酒类别-紫葡萄酒。正德药业是由吉林紫鑫药业股份有限公司控制的品牌渠道企业,吉林紫鑫药业股份有限公司在深圳证券交易所上市。他负责购物中心的战略规划和生态链建设,这是“一带一路”倡议下的世界购物中心体系。他拥有北京中医药大学的学士学位。
Xiaodong Ji was appointed as our director on May 22 2021. Mr. Ji established Jiangsu Sutaitang E-Commerce Co., Ltd. “Sutaitang” in October 2019 and currently serves as the CEO of Sutaitang. He is also the deputy general manager of Jiangsu Health Pharmaceutical investment Co., Ltd. Mr. Ji has rich experience of two decades in corporation management, brand chain operation and marketing. Prior to joining us, Mr. Ji has served as CEOs of Dongfang Purple Wine, Zhengde Pharmaceutical, China Belt and Road Shopping Mall Co., Ltd. (the subsidiary of Zhong Zong Tou Group, “Shopping Mall”), respectively. Mr. Ji was responsible for the enterprise management and channel construction of Dongfang Purple Wine and Zhengde Pharmaceutical. Dongfang Purple Wine creates the fifth largest category of wine in China - Purple wine (purple wine is a fine wine made from mulberry fruit). Zhengde pharmaceutical is a brand channel enterprise controlled by Jilin Zixin Pharmaceutical Industrial Co., Ltd. which is listed on Shenzhen Stock Exchange. Mr. Ji was in charge of the strategic planning and ecological chain construction of Shopping Mall, which is a world shopping mall system under the Belt and Road Initiative. Mr. Ji earned his bachelor degree from Beijing University of Chinese Medicine.

高管简历

中英对照 |  中文 |  英文
周峰

周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。


Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。
Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
Wang L. Lee

Wang L. Lee。Lee先生于2021年2月1日被任命为中国苏轩堂药业有限公司的首席财务官。在加入中国苏轩堂药业有限公司之前,Lee先生于2019年1月至2020年4月担任万达体育集团有限公司纳斯达克:WSG的证券运营董事。他从赛科控股有限公司(纳斯达克代码:SECO)加入万达体育,并于2017年5月至2019年12月担任财务报告总监。Lee先生于2001年获得休斯顿大学工商管理学士学位,是德克萨斯州的注册会计师。


Wang L. Lee was appointed as our Chief Financial Officer on February 1 2021. Prior to joining the Company, Mr. Lee acted as the Securities Operation Director at Wanda Sports Group Co., Ltd. NASDAQ: WSG from January 2019 and April 2020. He joined Wanda Sports from Secoo Holding Limited (NASDAQ: SECO), where he served as the Finance Reporting Director from May 2017 and December 2019. Mr. Lee earned his Bachelor of Business Administration Degree from University of Houston in 2001 and is a certified public accountant in Texas.
Wang L. Lee。Lee先生于2021年2月1日被任命为中国苏轩堂药业有限公司的首席财务官。在加入中国苏轩堂药业有限公司之前,Lee先生于2019年1月至2020年4月担任万达体育集团有限公司纳斯达克:WSG的证券运营董事。他从赛科控股有限公司(纳斯达克代码:SECO)加入万达体育,并于2017年5月至2019年12月担任财务报告总监。Lee先生于2001年获得休斯顿大学工商管理学士学位,是德克萨斯州的注册会计师。
Wang L. Lee was appointed as our Chief Financial Officer on February 1 2021. Prior to joining the Company, Mr. Lee acted as the Securities Operation Director at Wanda Sports Group Co., Ltd. NASDAQ: WSG from January 2019 and April 2020. He joined Wanda Sports from Secoo Holding Limited (NASDAQ: SECO), where he served as the Finance Reporting Director from May 2017 and December 2019. Mr. Lee earned his Bachelor of Business Administration Degree from University of Houston in 2001 and is a certified public accountant in Texas.
邓京振

邓京振自2017年3月起担任中国苏轩堂药业有限公司首席科学官(CSO)和首席营运官(COO)。 自2013年6月,邓博士担任江苏苏轩堂药业有限公司副总经理和首席科学官(CSO),并重建公司的研发团队。邓博士在美国大学及药企有着16年的研究和工作经历,尤其在天然产物(中药)和新药研究领域,有着16年的丰富经验,曾担任美国弗吉尼亚大学博士后研究员和美国药物研发公司主管。邓博士在中国有着14年的工作经历,曾在中国药科大学和江西中药研发机构任职,并曾担任上海RCT医药有限公司首席执行官(CEO)。通过建立新药研发策略,运用现代科技创新技术和方法,持续不断地研发新型现代中药饮片产品,以满足公司更高的新产品及产品质量的要求。邓博士于1982年获得江西中医学院理学学士学位,并于1989年和1992年分别获得中国药科大学理学硕士学位和博士学位。


Jingzhen Deng has been our CSO since June 2013 our COO since March 2017 and was CEO of Taizhou Suxuantang from February, 2018 to December 31 2019. He has been the vice president of Taizhou Suxuantang in June 2013 and rebuilt its R&D team. Dr. Deng has 16 years of experience at a university University of Virginia as a postdoctoral scientist and various pharmaceutical companies (Pinnacle Pharmaceuticals, Inc. and Drumetix Laboratories, as directors of R&D) specializing in natural products and new drug discovery in the USA, and more than 14 years at a Traditional Chinese Medicine (“TCM”) related university (China Pharmaceutical University), institute (Jiangxi Institute of TCM), and pharmaceutical company (RCT Pharmaceuticals, Inc. as CEO in Shanghai) in China. He established the general R&D strategy of using modern technology to revolutionize TCMP production, and continue developing newly advanced and non-decocting TCMP/TCM products capable of meeting the highest quality standard at the company. Dr. Deng received his Bachelor of Science from Jiangxi University of Traditional Chinese Medicine in 1982 Master and Doctoral degrees from China Pharmaceutical University in 1989 and 1992 respectively.
邓京振自2017年3月起担任中国苏轩堂药业有限公司首席科学官(CSO)和首席营运官(COO)。 自2013年6月,邓博士担任江苏苏轩堂药业有限公司副总经理和首席科学官(CSO),并重建公司的研发团队。邓博士在美国大学及药企有着16年的研究和工作经历,尤其在天然产物(中药)和新药研究领域,有着16年的丰富经验,曾担任美国弗吉尼亚大学博士后研究员和美国药物研发公司主管。邓博士在中国有着14年的工作经历,曾在中国药科大学和江西中药研发机构任职,并曾担任上海RCT医药有限公司首席执行官(CEO)。通过建立新药研发策略,运用现代科技创新技术和方法,持续不断地研发新型现代中药饮片产品,以满足公司更高的新产品及产品质量的要求。邓博士于1982年获得江西中医学院理学学士学位,并于1989年和1992年分别获得中国药科大学理学硕士学位和博士学位。
Jingzhen Deng has been our CSO since June 2013 our COO since March 2017 and was CEO of Taizhou Suxuantang from February, 2018 to December 31 2019. He has been the vice president of Taizhou Suxuantang in June 2013 and rebuilt its R&D team. Dr. Deng has 16 years of experience at a university University of Virginia as a postdoctoral scientist and various pharmaceutical companies (Pinnacle Pharmaceuticals, Inc. and Drumetix Laboratories, as directors of R&D) specializing in natural products and new drug discovery in the USA, and more than 14 years at a Traditional Chinese Medicine (“TCM”) related university (China Pharmaceutical University), institute (Jiangxi Institute of TCM), and pharmaceutical company (RCT Pharmaceuticals, Inc. as CEO in Shanghai) in China. He established the general R&D strategy of using modern technology to revolutionize TCMP production, and continue developing newly advanced and non-decocting TCMP/TCM products capable of meeting the highest quality standard at the company. Dr. Deng received his Bachelor of Science from Jiangxi University of Traditional Chinese Medicine in 1982 Master and Doctoral degrees from China Pharmaceutical University in 1989 and 1992 respectively.